Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 17/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633767 | 0.92 | FOLH1 (0.46) | FOLH1LTB4RLTB4R2ALB | |
| SCHEMBL19633798 | 0.92 | FOLH1 (0.49) | FOLH1ALB | |
| SCHEMBL19633768 | 0.88 | ALB (0.50) | FOLH1ALB | |
| SCHEMBL27098049 | 0.88 | FOLH1 (0.41) | FOLH1ALB | |
| SCHEMBL27098050 | 0.88 | FOLH1 (0.37) | FOLH1ALB | |
| SCHEMBL27098048 | 0.88 | FOLH1 (0.37) | FOLH1ALB | |
| SCHEMBL27098046 | 0.88 | FOLH1 (0.37) | FOLH1ALB | |
| SCHEMBL19633686 | 0.88 | FOLH1 (0.51) | TGM2FOLH1 | |
| SCHEMBL19633773 | 0.79 | FOLH1 (0.63) | FOLH1 | |
| SCHEMBL27098294 | 0.79 | FOLH1 (0.50) | TGM2FOLH1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | TGM2 76/4885FOLH1 1/4885LTB4R 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.